SAMSUNG PHARM. Co., LTD.

KSE 001360.KS

SAMSUNG PHARM. Co., LTD. EBIT Margin for the year ending December 31, 2023: -45.43%

SAMSUNG PHARM. Co., LTD. EBIT Margin is -45.43% for the year ending December 31, 2023, a 5.75% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

SAMSUNG PHARM. Co., LTD. EBIT Margin for the year ending December 31, 2022 was -48.20%, a 33.29% change year over year.
SAMSUNG PHARM. Co., LTD. EBIT Margin for the year ending December 31, 2021 was -72.24%, a -18.12% change year over year.
SAMSUNG PHARM. Co., LTD. EBIT Margin for the year ending December 31, 2020 was -61.16%, a -432.06% change year over year.
SAMSUNG PHARM. Co., LTD. EBIT Margin for the year ending December 31, 2019 was 18.42%, a 1,398.21% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

KSE: 001360.KS

SAMSUNG PHARM. Co., LTD.

CEO	Mr. Won-Kyu Kim
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	35 Jeyakgongdan 2-gil
Employees	240
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, mixed vitamins, antibiotics, and others. The company also provides medicines for digestive system, medicines for liver disorder, medicines for circulation system, cold medicines, nutritional supplements, health tonics, and others, as well as vitamins and energy drinks, and functional foods. The company was founded in 1929 and is based in Hwaseong-si, South Korea.

Key trends

Past 5 years